全肿瘤抗原疫苗。
Whole tumor antigen vaccines.
机构信息
Ovarian Cancer Research Center, University of Pennsylvania Medical Center, USA.
出版信息
Semin Immunol. 2010 Jun;22(3):132-43. doi: 10.1016/j.smim.2010.02.004. Epub 2010 Mar 30.
Abstract
Although cancer vaccines with defined antigens are commonly used, the use of whole tumor cell preparations in tumor immunotherapy is a very promising approach and can obviate some important limitations in vaccine development. Whole tumor cells are a good source of TAAs and can induce simultaneous CTLs and CD4(+) T helper cell activation. We review current approaches to prepare whole tumor cell vaccines, including traditional methods of freeze-thaw lysates, tumor cells treated with ultraviolet irradiation, and RNA electroporation, along with more recent methods to increase tumor cell immunogenicity with HOCl oxidation or infection with replication-incompetent herpes simplex virus.
摘要
虽然使用具有明确抗原的癌症疫苗很常见，但使用全肿瘤细胞制剂进行肿瘤免疫治疗是一种非常有前途的方法，可以避免疫苗开发中的一些重要限制。全肿瘤细胞是 TAA 的良好来源，并且可以诱导同时的 CTL 和 CD4(+)T 辅助细胞激活。我们综述了目前制备全肿瘤细胞疫苗的方法，包括传统的冻融裂解物方法、经紫外线照射处理的肿瘤细胞和 RNA 电穿孔，以及最近使用次氯酸氧化或感染无复制能力的单纯疱疹病毒来提高肿瘤细胞免疫原性的方法。
相似文献
1
Whole tumor antigen vaccines.全肿瘤抗原疫苗。
Semin Immunol. 2010 Jun;22(3):132-43. doi: 10.1016/j.smim.2010.02.004. Epub 2010 Mar 30.
2
A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.用自体次氯酸氧化卵巢癌细胞裂解物冲击的树突状细胞疫苗可诱导有效的广谱抗肿瘤免疫：从基础到临床。
Clin Cancer Res. 2013 Sep 1;19(17):4801-15. doi: 10.1158/1078-0432.CCR-13-1185. Epub 2013 Jul 9.
3
Immunogenic potential of three transmissible venereal tumor cell lysates to prime canine-dendritic cells for cancer immunotherapy.三种传染性性病肿瘤细胞裂解物对犬树突状细胞进行癌症免疫治疗的免疫原性潜力。
Res Vet Sci. 2018 Dec;121:23-30. doi: 10.1016/j.rvsc.2018.10.001. Epub 2018 Oct 5.
4
Clinically feasible approaches to potentiating cancer cell-based immunotherapies.增强基于癌细胞的免疫疗法的临床可行方法。
Hum Vaccin Immunother. 2015;11(4):851-69. doi: 10.1080/21645515.2015.1009814.
5
Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines.增强全肿瘤细胞疫苗免疫原性的佐剂。
Int Rev Immunol. 2011 Apr-Jun;30(2-3):150-82. doi: 10.3109/08830185.2011.572210.
6
The present status and future prospects of peptide-based cancer vaccines.基于肽的癌症疫苗的现状与未来前景。
Int Immunol. 2016 Jul;28(7):319-28. doi: 10.1093/intimm/dxw027. Epub 2016 May 28.
7
Tumor cell lysates as immunogenic sources for cancer vaccine design.肿瘤细胞裂解物作为癌症疫苗设计的免疫原性来源。
Hum Vaccin Immunother. 2014;10(11):3261-9. doi: 10.4161/21645515.2014.982996.
8
Dendritic Cells Loaded with Heat Shock-Conditioned Ovarian Epithelial Carcinoma Cell Lysates Elicit T Cell-Dependent Antitumor Immune Responses .负载热休克条件化卵巢上皮癌细胞裂解物的树突状细胞可诱导 T 细胞依赖的抗肿瘤免疫应答。
J Immunol Res. 2019 Nov 25;2019:9631515. doi: 10.1155/2019/9631515. eCollection 2019.
9
Direct vaccination with tumor cells killed with ICP4-deficient HSVd120 elicits effective antitumor immunity.用ICP4缺陷型单纯疱疹病毒d120杀死的肿瘤细胞进行直接疫苗接种可引发有效的抗肿瘤免疫。
Cancer Biol Ther. 2006 Jul;5(7):867-74. doi: 10.4161/cbt.5.7.2908. Epub 2006 Jul 18.
10
Preparation of apoptotic tumor cells with replication-incompetent HSV augments the efficacy of dendritic cell vaccines.用无复制能力的单纯疱疹病毒制备凋亡肿瘤细胞可增强树突状细胞疫苗的疗效。
Cancer Gene Ther. 2006 Feb;13(2):182-93. doi: 10.1038/sj.cgt.7700888.
引用本文的文献
1
Transforming Cancer Nanotechnology Data Analysis and User Experience. Part I: Current Challenges and Solutions Provided by caNanoLab.变革癌症纳米技术数据分析与用户体验。第一部分：caNanoLab 提供的当前挑战与解决方案。
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2025 Jul-Aug;17(4):e70030. doi: 10.1002/wnan.70030.
2
Lung cancer vaccine strategies: exploring the spectrum from traditional to RNA-based platforms.肺癌疫苗策略：探索从传统平台到基于RNA平台的范围
Front Bioeng Biotechnol. 2025 Jun 23;13:1617352. doi: 10.3389/fbioe.2025.1617352. eCollection 2025.
3
TMTP1-modified polymeric micelles for the inhibition of ovarian cancer metastasis and recurrence through enhanced photothermal-immunotherapy.经TMTP1修饰的聚合物胶束通过增强光热免疫疗法抑制卵巢癌转移和复发
Mater Today Bio. 2025 May 4;32:101825. doi: 10.1016/j.mtbio.2025.101825. eCollection 2025 Jun.
4
DCs pulsed with hypochlorous acid-treated tumor cell lysates present antigens efficiently and induce CD8 T cell activation through cross-presentation.用次氯酸处理的肿瘤细胞裂解物脉冲处理的树突状细胞能有效呈递抗原，并通过交叉呈递诱导CD8 T细胞活化。
Res Pharm Sci. 2025 Mar 31;20(2):230-240. doi: 10.4103/RPS.RPS_15_24. eCollection 2025 Apr.
5
Advancing Breast Cancer Treatment: The Role of Immunotherapy and Cancer Vaccines in Overcoming Therapeutic Challenges.推进乳腺癌治疗：免疫疗法和癌症疫苗在克服治疗挑战中的作用。
Vaccines (Basel). 2025 Mar 24;13(4):344. doi: 10.3390/vaccines13040344.
6
Tumor microenvironment and immunotherapy for triple-negative breast cancer.三阴性乳腺癌的肿瘤微环境与免疫治疗
Biomark Res. 2024 Dec 31;12(1):166. doi: 10.1186/s40364-024-00714-6.
7
Whole-Cell Vaccine Preparation Through Prussian Blue Nanoparticles-Elicited Immunogenic Cell Death and Loading in Gel Microneedles Patches.通过普鲁士蓝纳米颗粒引发免疫原性细胞死亡并负载于凝胶微针贴片制备全细胞疫苗
Gels. 2024 Dec 19;10(12):838. doi: 10.3390/gels10120838.
8
Immunotherapeutic advances in glioma management: The rise of vaccine-based approaches.免疫治疗在神经胶质瘤治疗管理中的进展：基于疫苗的方法的兴起。
CNS Neurosci Ther. 2024 Sep;30(9):e70013. doi: 10.1111/cns.70013.
9
Bibliometric analysis of dendritic cell-based vaccines over the past 15 years.过去 15 年基于树突状细胞的疫苗的文献计量分析。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2392961. doi: 10.1080/21645515.2024.2392961. Epub 2024 Aug 19.
10
Intradermal vaccination with a phytoglycogen nanoparticle and STING agonist induces cytotoxic T lymphocyte-mediated antitumor immunity.用植物糖原纳米颗粒和STING激动剂进行皮内接种可诱导细胞毒性T淋巴细胞介导的抗肿瘤免疫。
NPJ Vaccines. 2024 Aug 17;9(1):149. doi: 10.1038/s41541-024-00943-8.
本文引用的文献
1
Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes.上皮内CD8阳性T淋巴细胞可预测浆液性III期卵巢癌患者的生存率：T淋巴细胞克隆选择的相关性
Br J Cancer. 2009 Nov 3;101(9):1513-21. doi: 10.1038/sj.bjc.6605274. Epub 2009 Sep 29.
2
Targets of protective tumor immunity.保护性肿瘤免疫的靶点。
Ann N Y Acad Sci. 2009 Sep;1174:74-80. doi: 10.1111/j.1749-6632.2009.04938.x.
3
Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors.高级别浆液性卵巢癌免疫浸润的系统分析显示，CD20、FoxP3和TIA-1为阳性预后因素。
PLoS One. 2009 Jul 29;4(7):e6412. doi: 10.1371/journal.pone.0006412.
4
Endothelin B receptor, a new target in cancer immune therapy.内皮素B受体，癌症免疫治疗的新靶点。
Clin Cancer Res. 2009 Jul 15;15(14):4521-8. doi: 10.1158/1078-0432.CCR-08-0543. Epub 2009 Jun 30.
5
Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer.上皮内T细胞与肿瘤增殖：对晚期浆液性卵巢癌手术细胞减灭术获益的影响
Cancer. 2009 Jul 1;115(13):2891-902. doi: 10.1002/cncr.24317.
6
Cellular immunotherapy for ovarian cancer.卵巢癌的细胞免疫疗法。
Expert Opin Biol Ther. 2009 Jun;9(6):677-88. doi: 10.1517/14712590902932897.
7
Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells.接受树突状细胞疫苗接种的黑色素瘤患者的长期存活与肿瘤特异性迟发型IV型超敏反应以及表达肿瘤生长因子β的T细胞数量减少相关。
J Clin Oncol. 2009 Feb 20;27(6):945-52. doi: 10.1200/JCO.2008.18.0794. Epub 2009 Jan 12.
8
Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss.上皮内T细胞与卵巢癌预后：与分期、肿瘤类型及BRCA1缺失的新关联
Mod Pathol. 2009 Mar;22(3):393-402. doi: 10.1038/modpathol.2008.191. Epub 2008 Dec 5.
9
Antigens for cancer immunotherapy.癌症免疫疗法的抗原。
Semin Immunol. 2008 Oct;20(5):286-95. doi: 10.1016/j.smim.2008.09.006. Epub 2008 Oct 23.
10
Oxidation of ovarian epithelial cancer cells by hypochlorous acid enhances immunogenicity and stimulates T cells that recognize autologous primary tumor.次氯酸对卵巢上皮癌细胞的氧化作用增强了免疫原性，并刺激了识别自体原发性肿瘤的T细胞。
Clin Cancer Res. 2008 Aug 1;14(15):4898-907. doi: 10.1158/1078-0432.CCR-07-4899.
Zotero 插件